DK3046548T3 - Tablet, der omfatter crospovidon - Google Patents

Tablet, der omfatter crospovidon Download PDF

Info

Publication number
DK3046548T3
DK3046548T3 DK14766730.7T DK14766730T DK3046548T3 DK 3046548 T3 DK3046548 T3 DK 3046548T3 DK 14766730 T DK14766730 T DK 14766730T DK 3046548 T3 DK3046548 T3 DK 3046548T3
Authority
DK
Denmark
Prior art keywords
crospovidon
table including
including crospovidon
Prior art date
Application number
DK14766730.7T
Other languages
English (en)
Inventor
Abraham Cornelis Lardée
Original Assignee
Centrient Pharmaceuticals Netherlands B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centrient Pharmaceuticals Netherlands B V filed Critical Centrient Pharmaceuticals Netherlands B V
Application granted granted Critical
Publication of DK3046548T3 publication Critical patent/DK3046548T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/424Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • A61K31/43Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK14766730.7T 2013-09-20 2014-09-18 Tablet, der omfatter crospovidon DK3046548T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13185368 2013-09-20
PCT/EP2014/069852 WO2015040093A1 (en) 2013-09-20 2014-09-18 Tablet comprising crospovidone

Publications (1)

Publication Number Publication Date
DK3046548T3 true DK3046548T3 (da) 2020-04-27

Family

ID=49223642

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14766730.7T DK3046548T3 (da) 2013-09-20 2014-09-18 Tablet, der omfatter crospovidon

Country Status (11)

Country Link
US (1) US10159647B2 (da)
EP (1) EP3046548B1 (da)
CN (1) CN105555261B (da)
DK (1) DK3046548T3 (da)
ES (1) ES2780874T3 (da)
HU (1) HUE048496T2 (da)
PL (1) PL3046548T3 (da)
PT (1) PT3046548T (da)
RS (1) RS60054B1 (da)
SI (1) SI3046548T1 (da)
WO (1) WO2015040093A1 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
US20200315972A1 (en) * 2019-03-11 2020-10-08 Gilead Sciences, Inc. Formulations of a compound and uses thereof
KR20230039717A (ko) * 2020-07-24 2023-03-21 디에스엠 아이피 어셋츠 비.브이. 새로운 급속 용해성 정제
CN113274357B (zh) * 2021-05-28 2022-12-27 广州白云山医药集团股份有限公司白云山制药总厂 一种阿莫西林药物及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI9200139A (en) 1992-07-08 1994-03-31 Lek Tovarna Farmacevtskih New inclusion complex of clavulanic acid with hydrophylyc and hydropholyc beta-cyclodextrin derivates for production of them
US20030124187A1 (en) * 1997-02-14 2003-07-03 Smithkline Beecham Laboratoires Pharmaceutiques, Pharmaceutical formulations comprising amoxycillin and clavulanate
TR199901961T2 (xx) 1997-02-14 1999-11-22 Smith Kline Beecham Laboratoires Pharmaceutiques Amoksosilin ve klav�lanat i�eren ispen�iyariler.
US6878386B1 (en) 1999-04-13 2005-04-12 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
US20020006433A1 (en) * 1999-04-29 2002-01-17 Nigel P. Davidson Pharmaceutical formulations

Also Published As

Publication number Publication date
CN105555261B (zh) 2020-02-11
PT3046548T (pt) 2020-03-04
US10159647B2 (en) 2018-12-25
WO2015040093A1 (en) 2015-03-26
EP3046548A1 (en) 2016-07-27
SI3046548T1 (sl) 2020-04-30
HUE048496T2 (hu) 2020-07-28
CN105555261A (zh) 2016-05-04
EP3046548B1 (en) 2020-02-12
PL3046548T3 (pl) 2020-07-13
RS60054B1 (sr) 2020-04-30
ES2780874T3 (es) 2020-08-27
US20160193153A1 (en) 2016-07-07

Similar Documents

Publication Publication Date Title
FR3006466B3 (fr) .
BR302014001376S1 (pt) Configuração aplicada em bolsa.
DK3043778T3 (da) Farmaceutiske sammensætninger, der indeholder refametinib
BR302013003933S1 (pt) Configuração aplicada em mesa
DK2975030T3 (da) Dihydropyridazin-3,5-dion-derivat
DK3003278T3 (da) Slugbare n-acetylcystein-tabletter
DK3046548T3 (da) Tablet, der omfatter crospovidon
FR3001302B1 (fr) .
UY4324S (es) Mesa
FR3001303B1 (fr) .
UY4323S (es) Mesa
UA27966S (uk) Стіл
UA27188S (uk) Стіл
UA27095S (uk) Стіл
TH1501000108A (th) เม็ดกลมเล็กแบบผสม
UA26628S (uk) Стіл
UA26627S (uk) Стіл
ES1088255Y (es) Mesa
CL2013001495S1 (es) Mesa
BR302013005804S1 (pt) Configuração aplicada em prensa
FI10266U1 (fi) Vaneri
BR302013005320S1 (pt) Configuração aplicada em mesa
BR302013005226S1 (pt) Configuração aplicada em mesa
TH148359B (th) ไพรโรลิดีน-2-คาร์บอกซาไมด์ที่ถูกแทนที่
BR302013002403S1 (pt) Configuração aplicada em mesa